A 63-year-old woman experienced tumor progression on pembrolizumab but achieved a complete response sustained over three years with second-line chemotherapy. (International Cancer Conference Journal)
MSI-high CRC with NTRK fusion achieved complete response with FOLFOX-bevacizumab after immunotherapy failure
The CRC Digest